STAT

Biotech hedge fund titan Sam Isaly harassed, demeaned women for years, former employees say

NEW YORK — The founder of biotech’s largest and most powerful hedge fund has for years perpetuated a toxic culture of sexual harassment, former employees told STAT, routinely subjecting young female assistants to pornography in the workplace, lewd jokes, and pervasive sexist comments.

Five people who once worked at investing giant OrbiMed Advisors said Sam Isaly, the firm’s 72-year-old managing partner, kept a set of breast implants on his desk, palpating them like stress balls during idle conversation. He wantonly demeaned and verbally abused female employees, they said.

One woman said on several occasions, she glimpsed hardcore pornography playing on the large screens that dominated the trading room floor of the $15 billion fund.

Four women said they repeatedly complained about Isaly’s behavior to senior executives at OrbiMed, getting sympathy, but no action. Though their jobs paid well and came with many perks, the boorish environment eventually drove each to quit, the women said.

“I’m scarred,” Delilah Burke, who was Isaly’s assistant for about 18 months beginning in 2009, said in an interview with STAT. “I still have anxiety from that job — now, years later.”

Isaly denied allegations of sexual harassment and pornography in the workplace in a 90-minute interview with STAT on Monday at OrbiMed’s headquarters.

Moments after this story was published Tuesday evening, OrbiMed issued a statement saying, “The incidents cited are concerning and OrbiMed has retained the services of an outside independent law firm to investigate the matter. OrbiMed takes gender equality seriously and wishes to encourage a supportive work environment and equal opportunity for all employees.”

Earlier Tuesday, shortly before the story was published, OrbiMed partner Carter Neild had emailed STAT: “If this article proceeds I hope that you will be fair and focus on the person responsible, not the entire firm.”

During the Monday interview, surrounded by three colleagues and a crisis-management consultant, Isaly was by turns playful, withdrawn, and agitated, maintaining throughout that he had done nothing wrong. He paused after each question before saying “no” or “not to my

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks